Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets
Brian T. CastleiD, Carissa C. DockiD, Mahya HemmatiD, Susan KlineiD, Christopher James TignanelliiD, Radha RajasinghamiD, David MasopustiD, Paolo P. ProvenzanoiD, Ryan Andrew LangloisiD, Timothy W. SchackeriD, Ashley T. HaaseiD, David J. OddeiD
Abstract
Effective therapies for COVID-19 are urgently needed. Presently there are more than 800 COVID-19 clinical trials globally, many with drug combinations, resulting in an empirical process with an enormous number of possible combinations. To identify the most promising potential therapies, we developed a biophysical model for the SARS-CoV-2 viral cycle and performed a sensitivity analysis for individual model parameters and all possible pairwise parameter changes (162 = 256 possibilities). We found that model-predicted virion production is fairly insensitive to changes in most viral entry, assembly, and release parameters, but highly sensitive to some viral transcription and translation parameters. Furthermore, we found a cooperative benefit to pairwise targeting of transcription and translation, predicting that combined targeting of these processes will be especially effective in inhibiting viral production.Competing Interest StatementThe authors have declared no competing interest.View Full Text
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 17
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantitative modeling of SARS-CoV-2 replication reveals phase-specific bottlenecks and antiviral targets
Simon T. Herrmann, Timon Kapischke, … Lars Kaderali·bioRxiv·Aug 26, 2026
- Dynamics of SARS-CoV-2 host cell interactions inferred from transcriptome analyses
Lukas Adam, Megan Lynn Stanifer, … Stefan M. Kallenberger·Science SignalingPeer-reviewed·Sep 26, 2023
- Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds
D. A. Hoagland, D. J. B. Clarke, … B. R. tenOever·bioRxiv·Jul 12, 2020
- Triple Combination Nitazoxanide, Ribavirin, and Hydroxychloroquine results in the multiplicative reduction of in vitro SARS-CoV-2 viral replication
E. Lian, C. McAlister, … R. Perera·bioRxiv·Nov 25, 2020
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity
L. Diomede, S. Baroni, … M. Salmona·bioRxiv·Jul 30, 2021
- An Oral Combination therapy against SARS-CoV-2 based on Synergistic Action of Auranofin and Remdesivir.
Oyahida Khatun, Rohan Narayan, … Shashank Tripathi·bioRxiv·Dec 19, 2025